Drugs / Adv.RSV-hIL12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00301106 | Oct 2005 → Aug 2008 | breast cancer, metastatic malignant neoplasm | Max Sung | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adv.RSV-hIL12 | “Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene (Adv.RSV-hIL12, also termed ADV-hIL-12).” NCT00301106 ↗ |
| Known as | ADV-hIL-12 | “Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene (Adv.RSV-hIL12, also termed ADV-hIL-12).” NCT00301106 ↗ |
| Route | Other | “administered by percutaneous intratumoral injection” NCT00301106 ↗ |